Business Wire

BRIGHTCOVE

18.8.2020 15:02:14 CEST | Business Wire | Press release

Share
Streamed Video Content Dominates Media and Entertainment Consumption in Europe According to the Brightcove Q2 2020 Global Video Index

Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today published the Brightcove Q2 2020 Global Video Index Entertainment and Media Edition , which found that OTT streaming of entertainment content continued to dominate, even as governments began loosening stay-at-home restrictions. The data suggests that consumers’ media consumption habits may be permanently shifting away from linear TV, cementing streaming as the go-to choice for entertainment viewing.

Brightcove’s Q2 2020 Global Video Index analyzes hundreds of billions of recent data points from Brightcove’s customers globally to provide insights into how viewers are watching video content. The Q2 data shows that consumption of news and entertainment content nearly doubled (40%) from Q1 (23%) – a significant finding considering Q2 typically sees slower growth in video viewing compared to Q1. Looking at the first half of 2020 compared to 2019, the number of views overall is up more than 30%.

“Consumers in Europe continue to remain glued to their smartphones as we’ve seen mobile consumption surge for two consecutive quarters now,” said Jim O’Neill, Principal Analyst and Author of Brightcove’s Global Video Index. “This, in addition to video views on connected TVs continuing to grow, indicates consumers increasingly are turning to streaming devices to view entertainment content. This shift in consumption will only strengthen as connected TVs inevitably replace computers as the second preferred device for consumption – following mobile.”

Where consumers choose to view their content is also shifting. Connected TVs (CTVs) saw the most growth in Q2 (160% year-over-year), indicating a resurgence in larger screens as the viewing medium of choice for entertainment.

Other notable findings from the Brightcove Q2 2020 Global Video Index that are specific to Europe include:

  • Consumption peaked despite regions reopening. Video views were up 52% in Q2.
  • Smartphones are continuing to see spikes in consumption. Views on mobile devices increased by 69%, following Q1 in which mobile views more than doubled. Smartphones were also dominant across all content lengths in Q2.
  • CTVs saw a surge in use. Video views on CTVs were up 42% in Q2; 45% in April, 37% in May, and 44% in June. For the first six months of the year, views on CTVs grew 49%, the second biggest gain among devices. CTV viewers also watched content more than 3x as long as on any other device.

“2020 has become video’s evolutionary moment, and streaming entertainment video content is one area where we will continue to see growth,” said Jeff Ray, Brightcove CEO. “The crisis has impacted people at an emotional and financial level, making the need for human connection through video content more crucial than ever. We’re seeing this play out with the rise of streaming services subscriptions, indicating that the future of entertainment consumption lies in connected and mobile devices – linear television could soon be of the past.”

To download the complete Brightcove Q2 2020 Global Video Index Entertainment and Media Edition inclusive of all data, visit: https://www.brightcove.com/en/video-index

To learn more about this quarter’s findings, tune into an exclusive webinar with Jim O’Neill on September 15th. To register, visit: https://get.brightcove.com/global-video-index-2020-q2/

About the Global Video Index

Brightcove’s Global Video Index assesses more than 400 billion anonymized data points from Brightcove’s thousands of customers each quarter, drawing industry insights that can help guide strategic and tactical decisions for businesses of all sizes.

About Brightcove Inc. (NASDAQ: BCOV)

We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.

Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye